Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 19391-19400 Newer>

The Motley Fool December 26, 2006 Brian Lawler	2006 in Review: MedImmune Will the years ahead continue to be positive for the biopharma? Next year's guidance is for revenue to grow 15% over the $1.3 billion that is expected in 2006. Investors should watch to make sure this is possible.
The Motley Fool December 26, 2006 Alyce Lomax	2006 in Review: Starbucks When it comes to 2006, some Starbucks shareholders might miss the boring old days.
The Motley Fool December 26, 2006 Brian Lawler	InterMune's Secret Drug Surprise Shares of InterMune have risen after positive trial results for one of its top drug candidates. Investors, take note.
The Motley Fool December 26, 2006 David Meier	Walgreen Powers Ahead: Fool by Numbers The pharmacy retailer released its earnings for first-quarter 2007: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool December 26, 2006 Nathan Slaughter	2006 in Review: IMAX A failed buyout, an SEC inquiry, a class-action lawsuit, and now weak quarterly results -- a lot of problems to converge on one company at one time. Can IMAX find a way to right the ship?
The Motley Fool December 26, 2006 Nathan Slaughter	Previewing 2007: IMAX The company's had a troubled year, to say the least. What comes next? Bottom-feeders waiting on a quick bounce might wind up disappointed if the shares continue trading for about the price of a box of Raisinets.
The Motley Fool December 26, 2006 Rich Smith	3Com's Fortunes Improve 3Com is a stronger company today than it was last year. However, investors are cautioned to keep an eye on the firm's SEC filings.
The Motley Fool December 26, 2006 Selena Maranjian	Kiss Your Brokerage Goodbye If you're fed up with your brokerage and don't like having to pay that commission every time you buy or sell a stock or mutual fund, know that you have some choices.
The Motley Fool December 26, 2006 Brian Lawler	2006 in Review: Amgen For investors in shares of Amgen, it hasn't been a good year. The stock has been down more than 7% year to date. Despite this fact, Amgen has had successes on all fronts this year.
The Motley Fool December 26, 2006 Brian Lawler	Barely a Ripple for New River With New River's $2 billion market cap, no recurring revenues to speak of, and the terms of its partnership with Shire still uncertain, these shares are more than a tad too rich.
<Older 19391-19400 Newer> Return to current articles.